UPDATE: SVB Leerink Upgrades CymaBay Therapeutics To Outperform, Raises Target To $6 Notes Seladelpar 'findings are a near-best case scenario for CBAY, in our view, and would appear to reopen the door to develop seladelpar in both PBC and NASH'